MUC16 and colorectal carcinoma: These findings establish CA125, CEA, and CA19-9 as cornerstone biomarkers for mortality risk prediction in patients with CRC receiving reduced-dose 5-FU, with CRP serving as a valuable complementary inflammatory indicator warranting further validation in larger cohorts.